Mette Kirstine Agger - Net Worth and Insider Trading
Mette Kirstine Agger Net Worth
The estimated net worth of Mette Kirstine Agger is at least $30 Million dollars as of 2024-09-20. Mette Kirstine Agger is the Director, 10% Owner of scPharmaceuticals Inc and owns about 3,183,986 shares of scPharmaceuticals Inc (SCPH) stock worth over $17 Million. Mette Kirstine Agger is the Director, 10% Owner of Imara Inc and owns about 1,432,722 shares of Imara Inc (IMRA) stock worth over $9 Million. Mette Kirstine Agger is also the Director of Trevi Therapeutics Inc and owns about 1,151,544 shares of Trevi Therapeutics Inc (TRVI) stock worth over $4 Million. Details can be seen in Mette Kirstine Agger's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mette Kirstine Agger has not made any transactions after 2020-03-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mette Kirstine Agger
Mette Kirstine Agger Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mette Kirstine Agger owns 5 companies in total, including scPharmaceuticals Inc (SCPH) , Imara Inc (IMRA) , and Trevi Therapeutics Inc (TRVI) among others .
Click here to see the complete history of Mette Kirstine Agger’s form 4 insider trades.
Insider Ownership Summary of Mette Kirstine Agger
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
SCPH | scPharmaceuticals Inc | 2017-11-21 | director |
IMRA | Imara Inc | 2020-03-16 | director & 10 percent owner |
TRVI | Trevi Therapeutics Inc | 2019-05-09 | director |
2020-03-11 | director & 10 percent owner | ||
2023-11-02 | director |
Mette Kirstine Agger Latest Holdings Summary
Mette Kirstine Agger currently owns a total of 3 stocks. Among these stocks, Mette Kirstine Agger owns 3,183,986 shares of scPharmaceuticals Inc (SCPH) as of November 21, 2017, with a value of $17 Million and a weighting of 56.14%. Mette Kirstine Agger owns 1,432,722 shares of Imara Inc (IMRA) as of March 16, 2020, with a value of $9 Million and a weighting of 30.35%. Mette Kirstine Agger also owns 1,151,544 shares of Trevi Therapeutics Inc (TRVI) as of May 9, 2019, with a value of $4 Million and a weighting of 13.51%.
Latest Holdings of Mette Kirstine Agger
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
SCPH | scPharmaceuticals Inc | 2017-11-21 | 3,183,986 | 5.26 | 16,747,766 |
IMRA | Imara Inc | 2020-03-16 | 1,432,722 | 6.32 | 9,054,803 |
TRVI | Trevi Therapeutics Inc | 2019-05-09 | 1,151,544 | 3.50 | 4,030,404 |
Holding Weightings of Mette Kirstine Agger
Mette Kirstine Agger Form 4 Trading Tracker
According to the SEC Form 4 filings, Mette Kirstine Agger has made a total of 0 transactions in scPharmaceuticals Inc (SCPH) over the past 5 years. The most-recent trade in scPharmaceuticals Inc is the acquisition of 654,762 shares on November 21, 2017, which cost Mette Kirstine Agger around $9 Million.
According to the SEC Form 4 filings, Mette Kirstine Agger has made a total of 1 transactions in Imara Inc (IMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Imara Inc is the acquisition of 187,500 shares on March 16, 2020, which cost Mette Kirstine Agger around $3 Million.
According to the SEC Form 4 filings, Mette Kirstine Agger has made a total of 0 transactions in Trevi Therapeutics Inc (TRVI) over the past 5 years. The most-recent trade in Trevi Therapeutics Inc is the acquisition of 375,000 shares on May 9, 2019, which cost Mette Kirstine Agger around $4 Million.
Insider Trading History of Mette Kirstine Agger
- 1
Mette Kirstine Agger Trading Performance
GuruFocus tracks the stock performance after each of Mette Kirstine Agger's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mette Kirstine Agger is 37.85%. GuruFocus also compares Mette Kirstine Agger's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mette Kirstine Agger within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mette Kirstine Agger's insider trading performs compared to the benchmark.
Performance of Mette Kirstine Agger
Mette Kirstine Agger Ownership Network
Mette Kirstine Agger Owned Company Details
What does scPharmaceuticals Inc do?
Who are the key executives at scPharmaceuticals Inc?
Mette Kirstine Agger is the director of scPharmaceuticals Inc. Other key executives at scPharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , 10 percent owner 5am Partners Iv, Llc , and director & President and CEO John H Tucker .
scPharmaceuticals Inc (SCPH) Insider Trades Summary
Over the past 18 months, Mette Kirstine Agger made no insider transaction in scPharmaceuticals Inc (SCPH). Other recent insider transactions involving scPharmaceuticals Inc (SCPH) include a net purchase of 500,000 shares made by Orbimed Advisors Llc ,
In summary, during the past 3 months, insiders sold 0 shares of scPharmaceuticals Inc (SCPH) in total and bought 500,000 shares, with a net purchase of 500,000 shares. During the past 18 months, 0 shares of scPharmaceuticals Inc (SCPH) were sold and 500,000 shares were bought by its insiders, resulting in a net purchase of 500,000 shares.
scPharmaceuticals Inc (SCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.
scPharmaceuticals Inc Insider Transactions
Mette Kirstine Agger Mailing Address
Above is the net worth, insider trading, and ownership report for Mette Kirstine Agger. You might contact Mette Kirstine Agger via mailing address: C/o Scpharmaceuticals, Inc., 2400 District Avenue Suite 310, Burlington Ma 01830.